BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas-Reference-Cited by-同舟云学术

BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas

Published:2010-10 Issue:4 Volume:177 Page:1611-1617
ISSN:0002-9440
Container-title:The American Journal of Pathology
language:en
Short-container-title:The American Journal of Pathology

Author:

Wong Kwong-Kwok,Tsang Yvonne T.M.,Deavers Michael T.,Mok Samuel C.,Zu Zhifei,Sun Charlotte,Malpica Anais,Wolf Judith K.,Lu Karen H.,Gershenson David M.

Funder

Gynecologic Cancer Foundation; the National Institutes of Health, including The University of Texas MD Anderson Cancer Center Specialized Program of Research Excellence in Ovarian Cancer

MD Anderson's Cancer Center Support

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference44 articles.

1. Grading ovarian serous carcinoma using a two-tier system;Malpica;Am J Surg Pathol,2004

2. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data;Vang;Am J Surg Pathol,2008

3. Clinical behavior of stage II–IV low-grade serous carcinoma of the ovary;Gershenson;Obstet Gynecol,2006

4. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum;Schmeler;Gynecol Oncol,2008

5. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant;Gershenson;Gynecol Oncol,2009

Cited by 186 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-grade Anaplastic Transformation of Ovarian Serous Borderline Tumor;American Journal of Surgical Pathology;2024-07-19

2. Molecular Pathology of Ovarian Epithelial Neoplasms;Clinics in Laboratory Medicine;2024-06

3. Exploring novel approaches in the systemic therapy of low-grade serous carcinoma of the ovary: a literature review;Frontiers in Medicine;2024-05-21

4. Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas;The Journal of Molecular Diagnostics;2024-04

5. Alterations in the MAPK pathway: promising biomarkers for MEK1/2 inhibition;Gynecology and Pelvic Medicine;2024-03